Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

University of Calgary

$135,000.00

Cognitive function in a sleep clinic cohort of patients with obstructive sleep apnea

FY 2018-19

Summary
Obstructive sleep apnea (OSA) is a chronic medical condition where patients stop breathing during sleep due to recurrent collapse of their upper airway, causing low oxygen levels (called "hypoxemia") and disturbed sleep. OSA can lead to trouble with memory, concentration and decision making (termed "cognitive impairment") in some, but not all, patients. Similarly, treatment of OSA improves cognitive functioning in some, but not all, patients. Though hypoxemia and sleep disruption are the most likely mechanisms whereby OSA leads to cognitive impairment, the size of this effect may be modified by co-existing factors such as age, gender, sleepiness, cognitive reserve (the brain's ability to resist damage), genetics, other health conditions and medications. Also, how much these factors impact the benefits of treating OSA is not known. Thus, the objectives of this study are to 1) determine the prevalence and severity of cognitive impairment in OSA before, and after, treatment, and 2) identify patient traits (termed "biomarkers") that can help predict which patients are at the greatest risk for cognitive impairment and who may benefit the most from OSA treatment. Adults with suspected OSA will be recruited from 5 academic sleep centres in Calgary, Saskatoon, Vancouver, Montreal and Quebec City. Patients will complete sleep and medical questionnaires and undergo cognitive testing (tests of memory and decision making) at study entry and 3 years later. All patients diagnosed with OSA will be offered the gold-standard treatment of continuous positive airway pressure (CPAP) and their adherence to this therapy will be monitored. Blood samples will be taken at study entry for genetic analyses. The prevalence of cognitive impairment and its link to hypoxemia and disturbed sleep will be determined at study entry and 3 years later, while controlling for age, gender, sleepiness, cognitive reserve, genetics, other health conditions and medications, and adherence to CPAP treatment.
Program
CIHR Fellowship
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
396804
Name
Beaudin Andrew
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Cognitive function in a sleep clinic cohort of patients with obstructive sleep apnea
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Apolipoprotein E (Apoe); Biomarkers; Cognition; Electroencephalography (Eeg); Hypoxemia; Memory; Mild Cognitive Impairment; Obstructive Sleep Apnea; Phenotype
Abstract
Obstructive sleep apnea (OSA) is a chronic medical condition where patients stop breathing during sleep due to recurrent collapse of their upper airway, causing low oxygen levels (called "hypoxemia") and disturbed sleep. OSA can lead to trouble with memory, concentration and decision making (termed "cognitive impairment") in some, but not all, patients. Similarly, treatment of OSA improves cognitive functioning in some, but not all, patients. Though hypoxemia and sleep disruption are the most likely mechanisms whereby OSA leads to cognitive impairment, the size of this effect may be modified by co-existing factors such as age, gender, sleepiness, cognitive reserve (the brain's ability to resist damage), genetics, other health conditions and medications. Also, how much these factors impact the benefits of treating OSA is not known. Thus, the objectives of this study are to 1) determine the prevalence and severity of cognitive impairment in OSA before, and after, treatment, and 2) identify patient traits (termed "biomarkers") that can help predict which patients are at the greatest risk for cognitive impairment and who may benefit the most from OSA treatment. Adults with suspected OSA will be recruited from 5 academic sleep centres in Calgary, Saskatoon, Vancouver, Montreal and Quebec City. Patients will complete sleep and medical questionnaires and undergo cognitive testing (tests of memory and decision making) at study entry and 3 years later. All patients diagnosed with OSA will be offered the gold-standard treatment of continuous positive airway pressure (CPAP) and their adherence to this therapy will be monitored. Blood samples will be taken at study entry for genetic analyses. The prevalence of cognitive impairment and its link to hypoxemia and disturbed sleep will be determined at study entry and 3 years later, while controlling for age, gender, sleepiness, cognitive reserve, genetics, other health conditions and medications, and adherence to CPAP treatment.
Competitiondate
201811
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Beaudin, Andrew
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~
University of Calgary - $135,000 Grant (2018-19) | Canada Spends